Premium
Effects of vigabatrin on evoked potentials in epileptic patients.
Author(s) -
Cosi V,
Callieco R,
Galimberti CA,
Manni R,
Tartara A,
Mumford J,
Perucca E
Publication year - 1989
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1989.tb03463.x
Subject(s) - vigabatrin , somatosensory evoked potential , placebo , anesthesia , epilepsy , evoked potential , medicine , brainstem , psychology , anticonvulsant , audiology , neuroscience , alternative medicine , pathology
1. Somatosensory (SEP) brainstem auditory (BAEP) and visual (VEP) evoked potentials were determined before and after add‐on administration of vigabatrin (GVG) in patients with epilepsy. 2. At pre‐ treatment assessment SEP and BAEP parameters were usually found to be within normal limits, while P100 latencies of the VEP were abnormally prolonged in a considerable proportion of patients. 3. In a double‐ blind, placebo‐controlled trial in 22 patients GVG (1‐3 g day‐1 stratified according to body weight) given for 7 weeks did not modify any of the evoked potential parameters evaluated. 4. Eighteen patients were evaluated prospectively at regular intervals during long‐term GVG (2‐4 g day‐1) therapy with a mean follow up of 24 months (range 13‐42 months). SEP, BAEP and especially VEP parameters showed some interindividual variability, but the within patient variation was relatively small. No consistent important changes were seen in association with GVG, although a possible trend towards a shortening of BAEP latencies and P100 latencies was observed. 5. The relevance of these findings with respect to GVG safety is discussed.